Modality
Degrader
MOA
TNFi
Target
WRN
Pathway
T-cell
Pompe
Development Pipeline
Preclinical
~Apr 2024
→ ~Jul 2025
Phase 1
Oct 2025
→ May 2030
Phase 1Current
NCT07205877
737 pts·Pompe
2025-10→2030-05·Completed
737 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-05-084.1y awayPh2 Data· Pompe
Trial Timeline
Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P1/2
Complet…
Catalysts
Ph2 Data
2030-05-08 · 4.1y away
Pompe
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07205877 | Phase 1/2 | Pompe | Completed | 737 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| 369-789 | Hansoh Pharma | Phase 3 | PI3Kα |